Adis Journal Podcasts
NovoUnderstanding the Patient Journey in Extrapulmonary Neuroendocrine Carcinoma: A Podcast
- Episódios
- 131
- Publicação
- semanal
- Último episódio
- 3 nov 2026
Sobre o podcast
Listen to podcasts with key opinion leaders in multiple therapy areas, discussing hot topics including topic overviews, expert opinions and conference overviews. Brought to you by the Adis Journals Group, part of Springer Nature. The primary audience for these podcasts are healthcare professionals, and are published and citable through the journals.
Episódios 131
Understanding the Patient Journey in Extrapulmonary Neuroendocrine Carcinoma: A Podcast
In this podcast, Aman Chauhan from the Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA, Deborah Robertson, patient advocate, Lombard, IL, USA, and Susan …
Notas do episódio
In this podcast, Aman Chauhan from the Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA, Deborah Robertson, patient advocate, Lombard, IL, USA, and Susan Meckler-Plummer from Minkahz NETs Mission, Atlanta, GA, USA discuss the diagnosis and treatment of extrapulmonary neuroendocrine carcinoma, highlighting challenges and unmet needs from the perspectives of a medical oncologist, patient, caregiver, and patient advocacy group founder. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01262-9. All conflicts of interest can be found online. Open Access: This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Dengue Vodcast: Insights from Recent Infectious Disease Congresses
Dengue Vodcast: Insights from Recent Infectious Disease Congresses This podcast is published open access in Infectious Diseases and Therapy, and is fully citeable. You can access the original published podcast …
Notas do episódio
Dengue Vodcast: Insights from Recent Infectious Disease Congresses This podcast is published open access in Infectious Diseases and Therapy, and is fully citeable. You can access the original published podcast article through the Infectious Diseases and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40121-026-01428-y. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.A Podcast on Osimertinib After CRT in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
In this podcast, Thanyanan Reungwetwattana from the Division of Medical Oncology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, Kristin A. Higgins from the Department of …
Notas do episódio
In this podcast, Thanyanan Reungwetwattana from the Division of Medical Oncology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, Kristin A. Higgins from the Department of Radiation Oncology, City of Hope Cancer Center Atlanta, Atlanta, GA, USA, Ignacio Casarini from the Servicio Oncología, Hospital Bernardo Houssay, Mar del Plata, Buenos Aires, Argentina, and Suresh S. Ramalingam from the Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA discuss considerations surrounding the implementation of the LAURA (NCT03521154) regimen (osimertinib after chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer) in clinical practice, including the potential challenges for healthcare professionals and how they may be mitigated. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01250-z. All conflicts of interest can be found online. Open Access: This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Perspectives on 10 years of Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: A Podcast
In this podcast, Shailender Bhatia from the Division of Hematology and Oncology, Department of Medicine, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA …
Notas do episódio
In this podcast, Shailender Bhatia from the Division of Hematology and Oncology, Department of Medicine, University of Washington and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA, Sandra D’Angelo from the Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA, and Paul Nghiem from the Department of Dermatology, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA summarize key studies of ICIs in advanced MCC, including clinical trials and real-world studies, and discuss clinical evidence related to practical considerations, such as elective discontinuation of ICI treatment, and treatment of patients with immunocompromised or immunosuppressed status. They also discuss initial findings from studies of ICI-based combinations in patients with advanced MCC and ICI treatment in earlier stages of MCC, and highlight the emerging role of circulating tumor DNA for predicting disease recurrence. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01256-7. All conflicts of interest can be found online. Open Access: This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Management of Adverse Events Associated with MET TKIs in Patients with Advanced NSCLC: A Podcast Discussion
In this podcast, Wade T. Iams from the Greco-Hainsworth Centers for Research Tennessee Oncology, Nashville, TN, USA and Narjust Florez form the Dana-Farber Cancer Institute and the Harvard Medical School …
Notas do episódio
In this podcast, Wade T. Iams from the Greco-Hainsworth Centers for Research Tennessee Oncology, Nashville, TN, USA and Narjust Florez form the Dana-Farber Cancer Institute and the Harvard Medical School, Boston, MA, USA discuss safety considerations with MET TKI treatment for patients with METex14 skipping NSCLC. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01242-z. All conflicts of interest can be found online. Open Access: This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Risk of Recurrence in Patients with HR+/HER2− Early Breast Cancer: A Podcast
In this podcast, Maryam B. Lustberg from the Smilow Cancer Hospital at Yale, New Haven, CT, USA, Megan-Claire Chase, Life on the Cancer Train, Atlanta, GA, USA, Stacey Tinianov, Advocates for Collaborative …
Notas do episódio
In this podcast, Maryam B. Lustberg from the Smilow Cancer Hospital at Yale, New Haven, CT, USA, Megan-Claire Chase, Life on the Cancer Train, Atlanta, GA, USA, Stacey Tinianov, Advocates for Collaborative Education, Santa Cruz, CA, USA, and Kevin Kalinsky from the Winship Cancer Institute at Emory University, Atlanta, GA, USA discuss the risk of recurrence for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer including early and late risk of recurrence, discuss how risk is assessed, and examine the evolving treatment landscape for reducing risk.. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01241-0. All conflicts of interest can be found online. Open Access: This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Expert Perspectives on TGCT & the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025
Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast Discussion In this podcast article, the authors share their perspectives on …
Notas do episódio
Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast Discussion In this podcast article, the authors share their perspectives on current treatment for the rare, locally aggressive neoplasm, tenosynovial giant cell tumor (TGCT). They also discuss the patient care journey in the US, and highlight the clinical significance of the MANEUVER study findings. This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03725-x. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Four-Year Outcomes of Faricimab in Diabetic Macular Edema in the RHONE-X Extension Trial: A Podcast
This podcast is published open access in Ophthalmology and Therapy and is fully citeable. You can access the original published podcast article through the Ophthalmology and Therapy website and by using this …
Notas do episódio
This podcast is published open access in Ophthalmology and Therapy and is fully citeable. You can access the original published podcast article through the Ophthalmology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40123-026-01470-6. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Vodcast on Real-World Comparative OS and PFS of CDK4/6 Inhibitors Plus an AI in the P-VERIFY Study
In this podcast, Hope S. Rugo from the Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA provides an overview of two recent publications …
Notas do episódio
In this podcast, Hope S. Rugo from the Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA provides an overview of two recent publications reporting overall survival (OS) and real-world progression-free survival (rwPFS) results from P-VERIFY, a retrospective comparative effectiveness study of CDK4/6 inhibitors plus an aromatase inhibitor (AI) among patients with HR+/HER2− mBC treated in routine clinical practice in the USA. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01233-0. All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Subcutaneous Amivantamab and Lazertinib in PALOMA-3: Efficacy, Safety, and Administration: A Vodcast
In this podcast, Danny Nguyen from the Department of Medical Oncology & Therapeutics Research, City of Hope, Huntington Beach, CA, USA discusses clinical considerations for subcutaneous amivantamab dosing and …
Notas do episódio
In this podcast, Danny Nguyen from the Department of Medical Oncology & Therapeutics Research, City of Hope, Huntington Beach, CA, USA discusses clinical considerations for subcutaneous amivantamab dosing and administration, including premedications, prophylactic measures, dose modifications, management of adverse reactions, and switching between IV and SC amivantamab. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01248-7. All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Revolutionizing 2L+ Myeloma: A Podcast on the New Era of BCMA-Targeted Bispecific Antibody Therapies
In this podcast, 2 leading haematologists discuss the unmet needs in multiple myeloma in the second-line setting and beyond, considerations for treatment decisions, and the evolving treatment landscape with a …
Notas do episódio
In this podcast, 2 leading haematologists discuss the unmet needs in multiple myeloma in the second-line setting and beyond, considerations for treatment decisions, and the evolving treatment landscape with a focus on B-cell maturation antigen-targeted bispecific antibodies, a rapidly advancing class of treatments in this setting. This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03715-z. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Beyond Typical AMD: A Vodcast Exploring the Clinical and Therapeutic Landscape of PCV
This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the XX website and by using this link …
Notas do episódio
This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the XX website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03717-x. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access: This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.The Alternative Complement Pathway in IgA Nephropathy: A Podcast for Advanced Practice Providers
The Alternative Complement Pathway in IgA Nephropathy: A Podcast for Advanced Practice Providers This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original …
Notas do episódio
The Alternative Complement Pathway in IgA Nephropathy: A Podcast for Advanced Practice Providers This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the journal's website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03680-7. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access. This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Emerging role of PD-(L)1/VEGF bispecific antibodies for advanced renal cell carcinoma treatment
Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the …
Notas do episódio
Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape Podcast on the Emerging Role of PD-(L)1/VEGF Bispecific Antibodies in the Evolving Advanced Renal Cell Carcinoma Treatment Landscape In this podcast, the authors discuss existing clinical evidence with bispecific antibodies in other cancers and explore the rationale for evaluating the antitumor activity of PD-(L)1/VEGF bispecifics, either as monotherapy or in conjunction with other treatments in patients with advanced renal cell carcinoma. This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-026-00450-x. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Obesity, Liver Disease, and the Patient Voice: A Clinical Dialogue Podcast
This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link …
Notas do episódio
This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03648-7. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.HER2-Mutant Non-Small Cell Lung Cancer Podcast: Finding Patients (Episode 2)
In episode 2 in our podcast series, Vivek Subbiah from the Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA, and Martin Dietrich from the US Oncology Network and Cancer Care …
Notas do episódio
In episode 2 in our podcast series, Vivek Subbiah from the Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA, and Martin Dietrich from the US Oncology Network and Cancer Care Centers of Brevard, Orlando, FL, USA focus on the critical challenge of identifying patients with HER2-mutant non-small cell lung cancer (NSCLC). This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01215-2. All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.HER2-mutant Non-small Cell Lung Cancer Podcast: Knowledge Is Power (Episode 1)
In the first episode of our podcast series, Vivek Subbiah from the Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA, Martin Dietrich from the US Oncology Network and Cancer …
Notas do episódio
In the first episode of our podcast series, Vivek Subbiah from the Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA, Martin Dietrich from the US Oncology Network and Cancer Care Centers of Brevard, Orlando, FL, USA, and Xiuning Le from the University of Texas MD Anderson Cancer Center, Houston, TX, USA introduce the emerging landscape of HER2-mutant non-small cell lung cancer (NSCLC), highlighting its place within the broader context of lung cancer. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01214-3. All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Podcast 3: Collaborative Care to Improve Cardiovascular Outcomes in Type 2 Diabetes
Podcast Episode 3: How Can Physicians Work Collaboratively to Improve Cardiovascular Outcomes in Patients with Type 2 Diabetes? This podcast is published open access in Diabetes Therapy and is fully citeable …
Notas do episódio
Podcast Episode 3: How Can Physicians Work Collaboratively to Improve Cardiovascular Outcomes in Patients with Type 2 Diabetes? This podcast is published open access in Diabetes Therapy and is fully citeable. You can access the original published podcast article through the Diabetes Therapy website and by using this link: https://link.springer.com/article/10.1007/s13300-026-01857-5. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Empowering Patients: The Role of Shared Treatment Decision-Making in Advanced Bladder Cancer—A Podcast
In this podcast, authors discuss the concept of shared treatment decision-making and the range of considerations related to its application in the management of advanced bladder cancer. With the increasing …
Notas do episódio
In this podcast, authors discuss the concept of shared treatment decision-making and the range of considerations related to its application in the management of advanced bladder cancer. With the increasing focus on patient-centered care, shared treatment decision-making can help create individualised treatment plans for patients with advanced bladder cancer, which can be facilitated by in-depth discussions between patients, carers, and clinicians about treatment goals and the benefits and risks of available treatment options. This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03535-1. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Podcast 2: Heart Failure Management for Non-Specialists: Focus On SGLT2 Inhibitors
Podcast Episode 2: Heart Failure Management in Patients with Diabetes for Endocrinologists, Primary Care Physicians, and Noncardiologist Clinicians: Focus on SGLT2 Inhibitors This podcast is published open …
Notas do episódio
Podcast Episode 2: Heart Failure Management in Patients with Diabetes for Endocrinologists, Primary Care Physicians, and Noncardiologist Clinicians: Focus on SGLT2 Inhibitors This podcast is published open access in Diabetes Therapy and is fully citeable. You can access the original published podcast article through the Diabetes Therapy website and by using this link: https://link.springer.com/article/10.1007/s13300-026-01856-6. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Podcast 1: Pragmatic Overview of Heart Failure for Non-Specialists
Podcast Episode 1: A Pragmatic Overview of Heart Failure in Patients with Diabetes for Endocrinologists, Primary Care Physicians and Noncardiologist Clinicians This podcast is published open access in Diabetes …
Notas do episódio
Podcast Episode 1: A Pragmatic Overview of Heart Failure in Patients with Diabetes for Endocrinologists, Primary Care Physicians and Noncardiologist Clinicians This podcast is published open access in Diabetes Therapy and is fully citeable. You can access the original published podcast article through the Diabetes Therapy website and by using this link: https://link.springer.com/article/10.1007/s13300-026-01855-7. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Overcoming Hyperkalaemia as a Barrier to Achieving Optimal RAASi Therapy in Individuals with Cardiorenal Disease
Overcoming Hyperkalaemia as a Barrier to Achieving Optimal RAASi Therapy and Cardiorenal Protection in Individuals with Cardiorenal Disease: A Podcast Discussion This podcast is published open access in …
Notas do episódio
Overcoming Hyperkalaemia as a Barrier to Achieving Optimal RAASi Therapy and Cardiorenal Protection in Individuals with Cardiorenal Disease: A Podcast Discussion This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03518-2. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access. This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Podcast: Adherence to Injectables
[FULL TITLE OF PODCAST IF ABRIDGED VERSION PROVIDED] This podcast is published open access in Dermatology and Therapy and is fully citeable. You can access the original published podcast article through the XX …
Notas do episódio
[FULL TITLE OF PODCAST IF ABRIDGED VERSION PROVIDED] This podcast is published open access in Dermatology and Therapy and is fully citeable. You can access the original published podcast article through the XX website and by using this link: https://link.springer.com/article/10.1007/s13555-026-01678-1. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.First Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options—A Podcast
In this podcast, Eric K. Singhi from the University of Texas MD Anderson Cancer Center, Houston, TX, USA, and Eric S. Nadler from the Baylor University Medical Center, Dallas, TX, USA discuss the available …
Notas do episódio
In this podcast, Eric K. Singhi from the University of Texas MD Anderson Cancer Center, Houston, TX, USA, and Eric S. Nadler from the Baylor University Medical Center, Dallas, TX, USA discuss the available treatment options for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) and focus on the efficacy and safety of first-line treatments and sequencing strategies. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-025-01192-y. All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Social Determinants of Health in Metastatic Breast Cancer Care: A Podcast Exploring Challenges and Opportunities in the
This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link …
Notas do episódio
This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00406-7. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Burgeoning Non-Muscle Invasive Bladder Cancer Space: AUA 2025 Clinical Trials Presented (Doctor/Patient Podcast)
In this plain language podcast, the authors discuss highlights from the American Urological Association (AUA) Annual Meeting 2025. These insights come from the perspective of an expert patient and physician …
Notas do episódio
In this plain language podcast, the authors discuss highlights from the American Urological Association (AUA) Annual Meeting 2025. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of bladder cancer. This podcast is intended to broaden the reach of complex data and insights from AUA 2025 to a broader audience, including non-specialists, helping enable better informed treatment decisions between patients and healthcare professionals. The authors introduce the current treatment landscape for patients and discuss four clinical trials focusing on patients with bacillus Calmette-Guérin (BCG)-naïve and BCG-unresponsive high-risk non-muscle invasive bladder cancer (HR-NMIBC). This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00409-4. All conflicts of interest can be found online. This podcast is primarily intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.The Role of Comorbidities in Treatment Decision-Making across the Spectrum of Prostate Cancer: A Podcast
Managing prostate cancer today means balancing cancer control with overall health and wellbeing. This episode explores how chronic conditions, frailty, and quality-of-life considerations shape treatment choices …
Notas do episódio
Managing prostate cancer today means balancing cancer control with overall health and wellbeing. This episode explores how chronic conditions, frailty, and quality-of-life considerations shape treatment choices from localised to advanced disease. Authors discuss why survival data has shifted the rationale for radical interventions, the complexities introduced by systemic therapy, and why assessing physiological age matters more than chronological age. Discover how comprehensive geriatric assessment supports personalised care, and how holistic, multidisciplinary decision-making can align treatment with life expectancy, patient preference, and independence. This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00407-6. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025: A Podcast
In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed. These insights come from the perspective of an expert patient and physician …
Notas do episódio
In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of prostate cancer. This podcast is intended to broaden the reach of complex data and insights from ASCO 2025 to a broader audience, including non-specialists, helping enable better-informed treatment decisions between patients and healthcare professionals. This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00403-w. All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. This podcast is intended for medical professionals.Bronchiectasis Treatment Goals, Unmet Needs, and Emerging Therapies: A Podcast
This podcast is published open access in Pulmonary Therapy and is fully citeable. You can access the original published podcast article through the Pulmonary Therapy website and by using this link …
Notas do episódio
This podcast is published open access in Pulmonary Therapy and is fully citeable. You can access the original published podcast article through the Pulmonary Therapy website and by using this link: https://link.springer.com/article/10.1007/s41030-025-00330-1. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.Real-World Perspectives on Switching Patients With Multiple Sclerosis From Anti-CD20 Therapy to Cladribine Tablets...
Real-World Perspectives on Switching Patients With Multiple Sclerosis From Anti-CD20 Therapy to Cladribine Tablets From US-Based Advanced Practice Providers: A Podcast This podcast is published open access in …
Notas do episódio
Real-World Perspectives on Switching Patients With Multiple Sclerosis From Anti-CD20 Therapy to Cladribine Tablets From US-Based Advanced Practice Providers: A Podcast This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-025-03391-5. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Aqui estão os 40 episódios mais recentes de 131. Os mais antigos estão no feed do podcast.
Podcasts parecidos
Mais podcasts de Saúde e fitness
Este podcast é seu?
Confirme com uma entrada no seu feed: você recebe um código aqui, adiciona como podcast:txt no canal do seu feed e nós verificamos. Depois disso, seu podcast aparece como “verificado” no SoundNode.